アジェンダ
9:40 AM — 10:00 AM
Facilitating the Development and Availability of COVID-19 Vaccine9:40 AM — 11:40 AM
Session 1 : Regulatory Trends in Response to COVID-1910:00 AM — 10:20 AM
Efforts to Facilitate the Development of Anti-SARS-CoV-2 Monoclonal Antibodies1:00 PM — 1:40 PM
Development Strategy of Molnupiravir1:00 PM — 3:00 PM
Session 2 : COVID-19 Treatment Development Experiences3:20 PM — 4:00 PM
BNT162b2 COVID-19 Vaccine - From Hope to Reality in 9 Months3:20 PM — 5:30 PM
Session 3 : COVID-19 Vaccine Development Strategy4:40 PM — 5:20 PM
Considerations for COVID-19 Vaccine Clinic Trials9:30 AM — 9:40 AM
9:30 AM — 9:40 AM
Opening: Access to Innovative Medicines in Korea9:40 AM — 11:00 AM
Session 4 : Korea’s Strategy for going Global10:00 AM — 10:20 AM
New Drug Development and IP Strategy10:20 AM — 11:00 AM
Clinical Develoment Strategy11:20 AM — 12:40 PM
Session 5 : Effective Method for Accelerating Drug Development12:00 PM — 12:40 PM
Use of Real-World Data and Real-World Evidence in Drug Development and Approvals2:00 PM — 3:30 PM
Session 6 : Development of Innovative Drug2:40 PM — 3:30 PM
Clinical Trials for Expedited Review and Development Programs